FDA seeks more COI (conflict of interest) information from advisory panellists
This article was originally published in Clinica
Executive Summary
Experts who participate on US FDA product specific advisory panels are to be asked to provide more detailed information about their potential financial conflicts than they have in the past. Under a new conflict of interest (COI) policy, experts must categorise the size of their stock holdings, their consulting fees, their contracts and grants and their teaching speaking or writing fees. The disclosures will identify whether the interest is related to the sponsor or competitor that markets a competing product and whether the expert worked on the competing product or not.